NEW YORK (GenomeWeb) – Adaptive Biotechnologies said today that it has agreed to use its technology to measure the efficacy of Janssen's Darzalex (daratumumab) in multiple myeloma (MM).

Under the terms of the collaboration, Adaptive will use its NGS-based ClonoSeq assay to measure minimal residual disease (MRD) in MM patients treated with Darzalex in ongoing clinical trials. The two companies hope to demonstrate the clinical utility of monitoring MRD as a way of assessing the medication's effectiveness.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.